Status:
COMPLETED
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
45-100 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cance...
Eligibility Criteria
Inclusion
- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women
Exclusion
- Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).
Key Trial Info
Start Date :
February 6 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2017
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT00274469
Start Date
February 6 2006
End Date
January 13 2017
Last Update
September 6 2019
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Frederick, Maryland, United States, 21701
2
Research Site
St Louis, Missouri, United States, 63113
3
Research Site
Teaneck, New Jersey, United States, 07666
4
Research Site
Austin, Texas, United States, 78705